Equities

agilon health inc

AGL:NYQ

agilon health inc

Actions
Health CareHealth Care Providers
  • Price (USD)1.84
  • Today's Change0.06 / 3.37%
  • Shares traded768.72k
  • 1 Year change-84.45%
  • Beta0.5012
Data delayed at least 15 minutes, as of Nov 22 2024 17:26 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform3
Hold14
Sell2
Strong Sell1

Share price forecast in USD

The 15 analysts offering 12 month price targets for Agilon Health Inc have a median target of 2.50, with a high estimate of 11.00 and a low estimate of 1.75. The median estimate represents a 40.45% increase from the last price of 1.78.
High518.0%11.00
Med40.4%2.50
Low-1.7%1.75

Earnings history & estimates in USD

On Nov 07, 2024, Agilon Health Inc reported 3rd quarter 2024 losses of -0.29 per share.
The next earnings announcement is expected on Feb 25, 2025.
Average growth rate-357.14%
Agilon Health Inc reported annual 2023 losses of -0.64 per share on Feb 27, 2024.
Average growth rate-35.00%
More ▼

Revenue history & estimates in USD

Agilon Health Inc had 3rd quarter 2024 revenues of 1.45bn. This missed the 1.47bn consensus estimate of the 18 analysts following the company. This was 27.71% above the prior year's 3rd quarter results.
Average growth rate+7.27%
Agilon Health Inc had revenues for the full year 2023 of 4.32bn. This was 59.38% above the prior year's results.
Average growth rate+53.54%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.